OSCR
Oscar Health, Inc.
OSCR has the edge over SGHT overall, supported by stronger fundamentals and lower modeled downside.
SGHT
Sight Sciences, Inc.
SGHT offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SGHT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SGHT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SGHT PE Valuation
SGHT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SGHT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SGHT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SGHT on earnings quality, reporting a profit while its opponent remains loss making.
SGHT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.51 | +$0.39 |
| Q2 2026 | -$0.55 | +$0.41 |
| Q1 2026 | -$0.70 | +$0.28 |
| Q4 2025 | -$0.74 | +$0.29 |
| Q3 2025 | -$0.90 | +$0.12 |
| Q2 2025 | -$0.96 | +$0.11 |
| Q1 2025 | -$0.98 | +$0.14 |
| Q4 2024 | -$1.03 | +$0.11 |
SGHT is still losing money, but far less than before: $0.51 per share over the past year, against $2.81 at its worst in late 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SGHT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SGHT on profitability, with a higher operating margin.
SGHT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.9M | +25% |
| Q2 2026 | $23.4M | +20% |
| Q1 2026 | $19.7M | +13% |
| Q4 2025 | $20.4M | +6.9% |
| Q3 2025 | $19.9M | -1.2% |
| Q2 2025 | $19.6M | -8.5% |
| Q1 2025 | $17.5M | -9.1% |
| Q4 2024 | $19.1M | +1.7% |
SGHT's revenue has grown year over year for four quarters in a row: $25M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +15 points |
| Q2 2026 | -17% | +43 points |
| Q1 2026 | -63% | +16 points |
| Q4 2025 | -18% | +45 points |
| Q3 2025 | -40% | +16 points |
| Q2 2025 | -60% | -0.4 points |
| Q1 2025 | -79% | -2.7 points |
| Q4 2024 | -63% | -3.3 points |
SGHT's operating margin was −25% last quarter, up 15 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SGHT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SGHT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | +$6.4M |
| Q2 2026 | -$5.7M | +$2.1M |
| Q1 2026 | -$7.1M | +$4.5M |
| Q4 2025 | -$1.7M | +$1.9M |
| Q3 2025 | -$8.9M | -2958% |
| Q2 2025 | -$7.8M | +$1.8M |
| Q1 2025 | -$11.6M | -$1.7M |
| Q4 2024 | -$3.6M | +$3.2M |
SGHT has burned cash in almost every quarter: −$17M over the past year, against −$32M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SGHT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +621K shares |
| 1 year | +5.2% | +2.7M shares |
| 3 years | +13% | +6.5M shares |
| 5 years | +474% | +45.5M shares |
| Available history | +57% | +20.1M shares |
SGHT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SGHT Net Leverage
SGHT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SGHT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.4 | Overbought |
| Stochastic | 91.0 | Overbought |
SGHT's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SGHT PE vs Healthcare Sector
SGHT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
SGHT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 19% above |
| 20 week MA | $7.85 | 40% above |
| 50 week MA | $6.42 | 71% above |
| 100 week MA | $5.07 | 117% above |
| 200 week MA | $5.73 | 92% above |
SGHT has climbed back above all five of its weekly moving averages, and it's now 92% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SGHT on returns for 2026, with the stronger performance.
SGHT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $32.7 | $18.5 | -43% |
| 2022 | $18.5 | $12.1 | -35% |
| 2023 | $12.1 | $5.16 | -57% |
| 2024 | $5.16 | $3.57 | -31% |
| 2025 | $3.57 | $8.82 | +147% |
| 2026 YTD | $8.82 | $11.0 | +25% |
SGHT's yearly returns have swung widely, from +147% in 2025 to −57% in 2023. It's up 25% so far in 2026.